CN101229233A - Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof - Google Patents
Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof Download PDFInfo
- Publication number
- CN101229233A CN101229233A CNA2008103001439A CN200810300143A CN101229233A CN 101229233 A CN101229233 A CN 101229233A CN A2008103001439 A CNA2008103001439 A CN A2008103001439A CN 200810300143 A CN200810300143 A CN 200810300143A CN 101229233 A CN101229233 A CN 101229233A
- Authority
- CN
- China
- Prior art keywords
- ligustri lucidi
- fructus ligustri
- add
- liver
- medical material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicine preparation for reducing blood lipid and protecting livers and the preparation method thereof. The preparation utilizes ligustrum lucidum and tea polyphenol as main effective components which are mixed with olive oils and perillaseed oils to prepare various preparations of pharmaceutical importance according to conventional processes. The Chinese medicine preparation of the invention can not only significantly reduce blood lipid but also protect livers.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicine pharmacy, particularly relate to a kind of Chinese medicine preparation that is used for blood fat reducing and protects the liver and preparation method thereof.
Background technology
Hyperlipidemia is meant cholesterol in the blood plasma, triglyceride, phospholipid and the lipid compositions such as fat acid of fatization a kind of disease disease of increasing not.The too high reason of blood fat is that the fatty and cholesterol food of feed is too much, with inherited genetic factors etc. relation is arranged simultaneously." fat " in the blood plasma mainly is cholesterol and triglyceride, they are not individualism, but transported with the form of apolipoprotein, apolipoprotein mainly includes five kinds of Chylomicron (CM), very low density lipoprotein (VLDL) (VLDL), intermediate density lipoprotein (IDL) (IDL), low density lipoprotein, LDL (LDL) and high density lipoprotein (HDL).Hyperlipidemia is the risk factor of systemic atherosclerosis, as easy trouble coronary heart disease, and cerebrovascular sclerosis, peripheral angiopathy etc., few sporter's hyperlipidemia such as complicated hypertension, diabetes, or coronary heart disease is arranged, obesity, apoplexy family history, danger can increase 1-5 doubly.There are some researches prove, hyperlipemia, blood lipid level descends 1%, and the mortality rate of cardiovascular and cerebrovascular disease can descend 2%, and therefore, the blood fat reducing level is prevention and treats the important of cardiovascular and cerebrovascular disease and effective means.
Blood lipid-lowering medicine is wide in variety at present, effect is different, its mechanism of action is generally disturbs a certain or several links in the lipid metabolism process, as reduce lipid absorption or quicken the decomposition and the drainage of lipid, disturb the liver lactone proteic synthetic or stop lipoprotein in liver, to be conveyed into blood plasma, increase speed that lipoprotein removes etc. from serum.Chinese medicine commonly used has Xuezhikang etc.Western medicine Statins, fibrate are more remarkable to the curative effect of symptoms such as hyperlipidemia, but Western medicine can cause blood sugar increasing, feels sick, reactions such as diarrhoea and liver function injury in blood fat reducing at present.And Chinese medicine has good effect for reducing blood fat, and side effect is less, becomes the important selection of blood fat reducing.
Summary of the invention
Technical problem to be solved by this invention provides a kind of Chinese medicine preparation that is used for blood fat reducing and protects the liver and preparation method thereof, and it is to be key component with Fructus Ligustri Lucidi and tea polyphenols, tangible effect for reducing blood fat is arranged, and have the effect that protects the liver to a certain extent.
In order to solve the problems of the technologies described above, the present invention adopts following technical scheme:
The present invention is used for blood fat reducing and the Chinese medicine preparation that protects the liver is to add adjuvant by Fructus Ligustri Lucidi medical material 1000～3000g, tea polyphenols 10～30g, olive oil 100～400g and perilla oil 100～400g to be prepared from.
Best, aforementioned Chinese medicine preparation is to add adjuvant by Fructus Ligustri Lucidi medical material 2000g, tea polyphenols 20g, olive oil 250g and perilla oil 250g to be prepared from.
The preparation method of the aforementioned Chinese medicine preparation that is used for blood fat reducing and protects the liver: get the Fructus Ligustri Lucidi medical material, through extract Fructus Ligustri Lucidi extract, add tea polyphenols, olive oil and perilla oil mix homogeneously then, add adjuvant routinely preparation process make various dosage forms.
The invention provides three kinds of extracting method of Fructus Ligustri Lucidi medical material:
Method one: get the Fructus Ligustri Lucidi medical material, pulverize and be coarse powder, with alcohol reflux three times, add 6～8 times of amount ethanol extractions 2 hours, merge extractive liquid, at every turn, filter, filtrate decompression is concentrated into 4～8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 10～20%, reflux 4～6 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60～80 ℃ of relative densities, adds 6～8 times of molten diffusing extractum of water gaging, regulates pH to 1.0～2.0 with 20～25% hydrochloric acid solutions, fully stir, left standstill 24 hours, and filtered, precipitation washes with water to pH 7.0, drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.
Method two: getting pulverizing is the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 6～8 times of amount ethanol extractions 2 hours at every turn, merge extractive liquid,, filter, filtrate decompression is concentrated into 4～8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 10～20%, reflux 4～6 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60～80 ℃ of relative densities, adds 4～8 times of molten diffusing extractum of water gaging, stir evenly, regulate pH 1.0～2.0 with 20～25% hydrochloric acid solutions, fully stir, add 1～5%NaCl (W/V, promptly in the solution of 100ml, add 1～5gNaCl) stirring and dissolving, left standstill 24 hours, and filtered, precipitation washes with water to pH 6.0～7.0, drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.
Method three: get pulverizing and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 6～8 times of amount ethanol extractions 2 hours at every turn, merge extractive liquid, filters, and filtrate decompression is concentrated into 4～8 times of Fructus Ligustri Lucidi medical material weight, the active carbon that adds Fructus Ligustri Lucidi medical material weight 10～20%, reflux 4～6 hours filters, and it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60～80 ℃ of relative densities, add 4～8 times of molten diffusing extractum of water gaging, stir evenly, add 3～7% clarifiers (W/V promptly adds 3～7g clarifier in the solution of 100ml) and fully stir, left standstill 24 hours, filter, drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract
Soft capsule preparation of the present invention is preparation like this: get light brown Fructus Ligustri Lucidi extract, tea polyphenols, olive oil, perilla oil and Cera Flava 1～3g and place material-compound tank, rotating speed with 5000～7000r/min grinds, get oily mixture, cross 80～100 mesh sieves, get implant, make the softgel shell glue with gelatin, adopt die pressing to make soft capsule.Wherein, die pressing is: the sprinkler body temperature is 50 ℃, under 18～20 ℃, humidity＜30% condition typing dry, dynamically air-dry 6～12 hours, clean the capsule outside, polishing, dry in the air ball 12～16 hours of room temperature promptly gets soft capsule preparation.
Powder of the present invention, tablet, capsule or granule are preparations like this: after getting gelatin 5g usefulness 60mL distilled water immersion 30min, in 60 ℃ of water-baths, dissolve to such an extent that gelatin solution is standby, light brown Fructus Ligustri Lucidi extract, tea polyphenols, olive oil and perilla oil are added in the gelatin solution, add 50 ℃ of distilled water after stirring to 100mL, stir, add the 60%Na of 50 ℃ of 200mL then
2SO
4Solution, mixing keeps mixed liquor at 50 ℃, stirs the 72%Na that adds 35～45 ℃ down
2SO
4Solution 500mL is chilled to 32～35 ℃ naturally, is placed in the ice-water bath below the rapid cooling to 10 ℃, constantly stir, add 37%HCHO solution 8mL, behind the stirring 20min, transfer to pH 9.0 with 20%NaOH, continue to stir 1h, centrifugal, divide and get microcapsule, it is formaldehydeless to be washed to neutrality, and lyophilization promptly gets exsiccant microcapsule, add adjuvant, make powder, capsule, tablet or granule according to conventional formulation technology.
Drop pill of the present invention is preparation like this: get gelatin 5～20g, glycerol 15～40g and water 50～200ml mix homogeneously, in 60～100 ℃ of heating in water bath 1 hour, adding Fructus Ligustri Lucidi extract and tea polyphenols while hot stirs, be chilled to 65 ℃, get rubber cement, standby 65 ℃ of insulations, olive oil and perilla oil after the preheating, are slowly added 20～100ml water in 60 ℃ of water-baths, stir 30min and carry out emulsifying under constantly stirring, under constantly stirring, slowly add in the rubber cement emulsion, stir and carried out emulsifying in 4 hours, with dosing pump dropping-pill machine system, 13～15 ℃ of liquid Paraffin are made condensed fluid, constant pressure and dry makes drop pill.
Fructus Ligustri Lucidi is cool in nature, and sweet in the mouth, hardship are returned liver, kidney channel, and the product for clear benefit have nourishing the liver and kidney, and the effect that black hair makes eye bright cures mainly the hepatic and renal YIN deficiency, and the head is giddy, Hiccough and deaf, early whitening of hair, diseases such as soreness of the waist and knees.Fructus Ligustri Lucidi is the dry mature fruit of Oleaceae plant Fructus Ligustri Lucidi.The name of Fructus Ligustri Lucidi, head sees Shennong's Herbal.Li Shizhen (1518-1593 A.D.) says, " it is verdant that this wood is insulted winter, the behaviour who has chastity to keep, so with chaste girl's shape it ".Shennong's Herbal is classified Fructus Ligustri Lucidi the top grade medicine of life lengthening as, can " main invigorating middle warmer, settling five organs are supported spirit, remove hundred diseases, and clothes are fertile strong for a long time, and it is not old to make light of one's life by commiting suicide ".Modern medicine study proves: Fructus Ligustri Lucidi can increase the coronary artery blood flow of laboratory animal, the effect of blood fat reducing, blood sugar lowering, blood viscosity lowering is arranged, antithrombotic and the atherosclerotic effect of control are arranged, the caused leukopenia of chemicotherapy there is the rising effect, according to the lipid peroxidation theory of aging, Fructus Ligustri Lucidi has certain anti-aging effects.Tea polyphenols is the general name of catechin in the Folium Camelliae sinensis, flavonoid, phenolic acids and anthocyan chemical compound, organic lipid metabolism is produced important effect, has the effect that cholesterol level rises in obvious suppression blood plasma and the liver, has the effect that promotes that lipoid substance is discharged from feces, therefore it not only can blood fat reducing, suppress atherosclerosis, and the effect of fat-reducing is arranged.Itself all has effect for reducing blood fat olive oil and perilla oil, and effects such as beauty treatment, blood fat reducing are arranged with olive oil separately.As a new force on the edible oil market, olive oil has the not available plurality of advantages of other edible oil: the health care of unique taste, abundant nutrition, beauty functions and control cardiovascular and cerebrovascular disease, and therefore be described as " liquid golden " by people.
The prescription screening experiment of Chinese medicine preparation of the present invention and said preparation in blood fat reducing and the detailed experimentation and the result of the effect aspect protecting the liver as follows:
One, research contents
Screen prescription of the present invention through gastric infusion, study its influence, the effect of observing its blood fat reducing and protecting the liver hyperlipidemia model rat fat and fatty liver.
Two, experiment material and method
Be subjected to the reagent thing: 5 groups of different formulations medicines are provided by the Guizhou Tongjitang Pharmaceutical Co., Ltd technique center;
The positive control medicine: XUEZHIKANG JIAONANG, the Beijing WBL Peking University Biotech Co., Ltd produces, commercially available finished product, lot number: 20061221.
Animal: SD rat, SPF level, 128, male and female half and half, body weight 180～220 gram, the laboratory animal certification of fitness number: 2006A051; The SPF level laboratory animal environmental condition quality certification number: 2006B023; SPF level laboratory animal production licence number: 2006-0015; Animal is provided by Nanfang Medical Univ zoopery center.
High lipid food: Adeps Sus domestica 12% (self-control); Cholesterol 2% (packing of Guangzhou southization glass company, 20061213); Propylthiouracil 0.2% (Shenzhen China Associated Pharmaceutical Co., Ltd., 0610312); No. 3 cholate 0.5% (Huankai Microbiological Science ﹠ Technolgy Co., Guangdong's packing, 200701023); Common mixed feed meal 85.3% (Nanfang Medical Univ zoopery center provides), with the artificial earlier fully mixing of above each thing, the reuse machine stirs, and is pressed into round strip particle, after the vacuum packaging, through Co
60Irradiation sterilization is standby, is made by Nanfang Medical Univ's Experimental Animal Center, and two months shelf-lifves are preserved in the shady and cool dry place sealing of ventilating.
Main chemical reagent and detecting instrument: formalin, analytical pure, lot number 20060606, Guangdong chemical reagent factory; Dehydrated alcohol, analytical pure, lot number 20060211, west, Shantou City, Guangdong Gansu Province Hua Chang; Dimethylbenzene, analytical pure, lot number 20061115, Shantou Xilong Chemical Factory, Guangdong; HAEMATOXYLIN, biological stain element, lot number 060408, Beijing ancient cooking vessel state Fluka of biotechnology Co., Ltd import packing; Eosin W or W S, biological stain element, lot number 040530, chemical scientific ﹠ technical corporation during Shanghai is new; OLYMPUSAU5421 type automatic clinical chemistry analyzer, Japanese OLYMPUS company produces; OLYMPUS BH-2 fluorescence microscope, Japanese OLYMPUS company produces; BECKMAN
TM30 type refrigerated centrifuges, U.S. BACKMAN company produces; LEICA RM2135 type microtome, German LEICA company produces; The SARTORIUS electronic balance, German SARTORIUS company produces.
5 groups of different formulations are subjected to reagent thing group, Xuezhikang group, model control group, normal control group and dosage:
1, the oil base group (olive oil and perilla oil mixed in equal amounts, 1ml/100g); 2, tea polyphenols (10.8mg/kg)+oil base group; 3, the refining extract (10.8mg/kg) of tea polyphenols (10.8mg/kg)+Fructus Ligustri Lucidi+oil base group; 4, the refining extract (10.8mg/kg) of Fructus Ligustri Lucidi+oil base group; 5, the Fructus Ligustri Lucidi crude extract (crude extract of Fructus Ligustri Lucidi 2160mg/kg)+oil base group; 6, Xuezhikang group (10.8mg/kg), commercially available finished product; 7, model control group; 8, normal control group.
Experimental technique:
Every group of 10 animals, male and female half and half.Except that the normal control group, all the other each treated animals all substitute normal diet with above-mentioned high lipid food and throw something and feed, on average about every about 20 grams every day.Normal control group and model control group are irritated the stomach tap water, and other each administration group is irritated stomach 1 time morning every day, and irritating the stomach volume is 1ml/100 gram rat.Above animal begins from modeling, 3 weeks of continuous irrigation stomach.Experiment finishes preceding 1 day evening and gives last 1 medicine and fasting, can't help water, and after the anesthesia in morning next day, the ventral aorta blood sampling send Hospital of Southern Medical University medical test center to detect five of blood fat.Get liver and claim the liver weight in wet base, from right lobe of liver isolated edge 1cm place, hepatic tissue of crosscut is fixed with neutral formalin, conventional dehydration, HE dyeing.Experimental data is represented with x ± SD and grade/frequency table data, adopts the spss8.0 One-Way ANOVA of statistical software LSD method and Nonparametric Test 2Independent Samples Tests method to carry out date processing.
Three, testing result:
1. the weight of animals changes
The rat body weight variation sees Table 1.
Table 1: each experimental group rat body weight situation of change (x ± SD, N=10, unit: g)
| Group | The 1st day | The 8th day | The 15th day | The 21st day | The 22nd day on an empty stomach |
| 1 | 193±12 | 204±14 | 210±19 | 212±20 | 203±18 |
| 2 | 192±9 | 203±11 | 208±17 | 215±20 | 207±19 |
| 3 | 193±14 | 199±22 | 202±23 | 204±26 | 198±25 |
| 4 | 191±16 | 187±18** | 202±24 | 207±24 | 198±24 |
| 5 | 192±17 | 191±24* | 196±24 | 200±24 | 193±23 |
| The Xuezhikang group | 192±14 | 198±16 | 212±20 | 218±21 | 206±19 |
| Model group | 193±13 | 208±14 | 212±18 | 214±17 | 204±15 |
| The normal control group | 192±15 | 239±22** | 260±25** | 279±39** | 256±37** |
Annotate: * and model control group compare, P＜0.05; * and model control group compare, P＜0.01.
2. feed consumption
The rat feed consumption sees Table 2.
Table 2: each experimental group rat feed consumption (N=10, unit: g)
| Group | The food consumption total amount | Average every rat feed consumption |
| 1 | 3248 | 324.8 |
| 2 | 3358 | 335.8 |
| 3 | 3237 | 323.7 |
| 4 | 3256 | 325.6 |
| 5 | 3328 | 332.8 |
| The Xuezhikang group | 3581 | 358.1 |
| Model group | 3481 | 348.1 |
| The normal control group | 5361 | 536.1 |
3. lipids detection result
The rat fat testing result sees Table 3.
Table 3: each experimental group rat fat testing result (N=10, x ± SD, unit: mmol/l)
| Group | Triglyceride | T-CHOL | High density lipoprotein | Low density lipoprotein, LDL | Very low density lipoprotein (VLDL) | The height than | Height is always than (%) |
| 1 | 0.24± 0.36** | 5.37± 3.40** | 0.67± 0.27** | 4.20± 2.82** | 0.50± 0.55* | 0.23± 0.18 | 16±10 |
| 2 | 0.60± 0.51** | 7.91± 3.81** | 0.78± 0.29** | 6.51± 3.38** | 0.62± 0.23* | 0.14± 0.05 | 11±3 |
| 3 | 0.34± 0.43** | 5.38± 3.96** | 0.74± 0.37** | 4.23± 3.44** | 0.42± 0.23** | 0.25± 0.21 | 17±9 |
| 4 | 0.56± 0.87** | 6.82± 6.45** | 0.79± 0.73** | 5.41± 5.14** | 0.62± 0.64* | 0.19± 0.13 | 14±7 |
| 5 | 0.32± 0.33** | 5.56± 1.62** | 0.60± 0.18** | 4.47± 1.55** | 0.49± 0.23* | 0.16± 0.13 | 12±8 |
| The Xuezhikang group | 0.92± 0.50* | 19.5± 8.64 | 2.36± 1.03* | 15.6± 6.75 | 1.57± 1.42 | 0.16± 0.04 | 13±3 |
| Model group | 1.37± 0.51 | 22.6± 6.57 | 2.91± 1.17 | 18.4± 4.73 | 1.31± 1.77 | 0.16± 0.04 | 13±2 |
| The normal control group | 0.30± 0.24** | 1.35± 0.14** | 0.96± 0.16** | 0.30± 0.10** | 0.09± 0.04** | 3.81± 2.08** | 71±8** |
Annotate: (1) .* and model control group compare, P＜0.05; * and model control group compare, P＜0.01.
(2). height is high density lipoprotein/low density lipoprotein, LDL than (H/L).
(3). height is high density lipoprotein/T-CHOL * 100% than (H/T) always.
(4). T-CHOL=high density lipoprotein+low density lipoprotein, LDL+very low density lipoprotein (VLDL)
(5). triglyceride, normal group and each administration group be no significant difference relatively.1st, 3 groups and the 2nd group have notable difference.
(6). T-CHOL, normal group and each administration group be no significant difference relatively.1st, 3 groups and the 2nd group have notable difference.
(7). high density lipoprotein, normal group and each administration group zero difference.
(8). low density lipoprotein, LDL, normal group and administration group have significant difference, and the 1st, 3 group and the 2nd group has notable difference.
(9). very low density lipoprotein (VLDL), normal group and each administration group zero difference.The 3rd group and the 2nd, 4 group has notable difference.
(10). the height than, normal group and each administration group all have significant differences (P＜0.01).The 3rd group and the 2nd group has notable difference.
(11). height always than, normal group and each administration group all have significant differences (P＜0.01).The 3rd group and the 2nd group has notable difference.
4. liver weight in wet base and liver index testing result see Table 4.
Each experimental group rats'liver weight in wet base of table 4 and liver index (N=10, x ± SD)
| Group | Animal example number (only) | Liver weight in wet base (g) | Liver index (%) |
| 1 | 10 | 7.97±1.01 | 3.92±0.24 |
| 2 | 10 | 8.13±1.43 | 3.91±0.41 |
| 3 | 10 | 7.33±1.51 | 3.68±0.32 |
| 4 | 10 | 7.71±1.63 | 3.86±0.48 |
| 5 | 10 | 7.26±1.30 | 3.75±0.36 |
| The Xuezhikang group | 10 | 8.59±1.36 | 4.17±0.40 |
| Model group | 10 | 8.01±0.72 | 3.94±0.23 |
| The normal control group | 10 | 7.35±1.35 | 2.86±0.21** |
Annotate: (1) .** and model control group compare, P＜0.01.
(2). the liver index is liver weight in wet base/rat limosis body weight * 100%
(3). the 3rd group has than notable difference with the Xuezhikang group.
5. the hepatic pathology histological examination the results are shown in Table 5
Table 5: each experimental group rat liver result of histopathologic examination
| Group | Normal liver tissue () (example) | Slight fatty liver (+) (example) | Moderate fatty liver (++) (example | Severe fatty liver (+++) (example) | The P value |
| 1 | 0 | 3 | 4 | 3 | 0.190 |
| 2 | 0 | 3 | 5 | 2 | 0.089 |
| 3 | 0 | 4 | 4 | 2 | 0.063 |
| 4 | 0 | 3 | 4 | 3 | 0.190 |
| 5 | 0 | 1 | 6 | 3 | 0.353 |
| The Xuezhikang group | 0 | 0 | 5 | 5 | 1.000 |
| Model group | 0 | 0 | 5 | 5 | |
| The normal control group | 10 | 0 | 0 | 0 | 0.000 |
To annotate: (1). normal control group and model control group compare, P＜0.01.
(2). the fatty liver grade scale, normal liver tissue (-): the lobules of liver structure is normal, liver rope queueing discipline, hepatocyte size uniformity, karyon is rounded, the form rule, most hepatocyte see a nucleus, the visible double-core of part.Kupffer does not have obvious hypertrophy.Portal area NIP cellular infiltration and proliferation of fibrous tissue, sinus hepaticus is high-visible; Slight fatty liver (+): the lobules of liver structure remains, and the hepatic tissue structure is roughly normal, part of hepatocytes rope arrangement disorder, and the sinus hepaticus stenosis, swelling of liver cell, slight cavity become and the change of balloon sample around the portal area; Moderate fatty liver (++): the lobules of liver structural fuzzy is unclear, the part of hepatocytes Cable Structure disappears, the hepatocyte arrangement disorder, and most of swelling of liver cell, cavity become and the balloon sample becomes, visible hepatocyte point-like of part animal and focal necrosis, a small amount of cell infiltration in portal area; Severe fatty liver (+++): the lobules of liver structure outline disappears, and the hepatocyte form is irregular, and most swelling of liver cell are the balloon sample and become, and visible vacuolar degeneration of hepatic cell, visible hepatocyte point-like of part animal or lamellar necrosis, portal area cell infiltration.
(3). the visible hepatocyte spotty necrosis of the 2nd group of 1 animal (♀ 8); The visible hepatocyte spotty necrosis of the 4th group of 1 animal (♂ 3), the visible hepatocyte focal necrosis of 2 animals (♂ 4, ♀ 8); The visible hepatocyte spotty necrosis of the 5th group of 1 animal (♂ 2), the visible hepatocyte focal necrosis of 1 animal (♀ 7); The visible hepatocyte office point shape necrosis of 1 animal of Xuezhikang group (♂ 1), the visible hepatocyte focal necrosis of 1 animal (♀ 6); The visible hepatocyte lamellar necrosis of 2 animals (♂ 3, ♂ 5); The visible hepatocyte spotty necrosis of 5 animals of model group (♂ 1, ♂ 5, ♀ 8, ♀ 9, ♀ 10), the visible hepatocyte focal necrosis of 1 animal (♀ 7).In the above-mentioned animal that hepatic necrosis occurs, a small amount of cell infiltration in visible minority animal liver tissue portal area.
(4). the 3rd group has notable difference with the 5th group, Xuezhikang group.
Four, experiment conclusion
1. the rats in normal control group body weight was higher than other each group (P＜0.01) on the 8th day later on very significantly in experiment; Between model control group and each the administration group, in experiment the 8th day the time, 5 groups and 4 groups of body weight are starkly lower than model control group (P＜0.05, P＜0.01).Tested the 1st day, the 15th day, the 22nd day, model control group and each administration group body weight no significant difference see Table 1.The normal rats body weight is higher than other group, and after this may form serious fatty liver with rat, influence was ingested and to influence body weight gain relevant.
2. the feed consumption of normal rats that gives normal feedstuff is apparently higher than other each group that gives high lipid food, and this may be because after rat formed serious fatty liver, influence was ingested.
3. learn from the data of table 3 that model control group gave high lipid food after 21 days, compare, serum triglycerides, T-CHOL, low density lipoprotein, LDL, very low density lipoprotein (VLDL) content highly significant rising (P＜0.01) with the normal control group; The ratio of the shared serum total cholesterol of serum high-density LP (H/T), model control group is starkly lower than the normal control group very much.1～5 group rat blood serum triglyceride, T-CHOL, low-density lipoprotein cholesterol, C-VLDL significantly are lower than model control group (P＜0.05, P＜0.01).The 3rd group with other groups notable difference is arranged.
4. from experimental result as can be seen, each experimental group rat fat liver alleviates, and is starkly lower than model control group (P＜0.05), Xuezhikang group and model control group comparison, and no significant difference, the 3rd group and model control group comparison have notable difference, see Table 5; The liver index also is the 3rd group to be reduced slightly, sees Table 4.
From above experimental result as can be known, the 3rd group has and reduces rat blood serum triglyceride, T-CHOL, low density lipoprotein, LDL, very low density lipoprotein (VLDL) effect significantly, and the effect that alleviates the rat fat liver is arranged.Analysis-by-synthesis relatively determines that the 3rd group is the prescription of Chinese medicine preparation of the present invention.From interpretation, the present invention has obvious effect for reducing blood fat, and hepatoprotective effect is to a certain degree arranged, and effect obviously is better than the positive control drug Xuezhikang.
Compared with prior art, the present invention is that the Fructus Ligustri Lucidi with tea polyphenols, medicine-food two-purpose is the primary raw material preparation, and be rich in oleic acid, linoleic olive oil and be rich in linolenic perilla oil, be function assessment functional component with heigh antioxidation effect, be again the substrate of each preparation.Existing hypolipidemic generally has only effect for reducing blood fat, the effect that does not protect the liver, and Chinese medicine preparation of the present invention not only has significant effect for reducing blood fat but also have obvious hepatoprotective effect.
The specific embodiment
Embodiment 1: Fructus Ligustri Lucidi medical material 2000g, tea polyphenols 20g, olive oil 250g, perilla oil 250g, Cera Flava 1.5g
Get to pulverize and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 7 times of amount ethanol extractions 1.5 hours at every turn, merge extractive liquid, filters, and filtrate decompression is concentrated into 6 times of Fructus Ligustri Lucidi medical material weight, the active carbon that adds Fructus Ligustri Lucidi medical material weight 15%, reflux 5 hours filters, and it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60 ℃ of relative densities, add 8 times of molten diffusing extractum of water gaging, be adjusted to pH1.5 with 20% hydrochloric acid solution, fully stir, left standstill 24 hours, filter, precipitation washes with water to pH7.0, and drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.Get light brown Fructus Ligustri Lucidi extract, tea polyphenols, olive oil, perilla oil and Cera Flava and place material-compound tank, with the rotating speed of 6000r/min grind oily mixture, cross 80～100 mesh sieves, implant.Gelatin is added transconversion into heat glue at 60～70 ℃, add plasticizer and pigment, make translucent glue, use the gelatin glue as softgel shell, adopt die pressing to prepare soft capsule preparation, sprinkler body temperature in the die pressing is 50 ℃, under 18～20 ℃, RH＜30% condition typing dry, dynamically air-dry 6～12 hours, cleaning capsule outside, dry in the air ball 12～16 hours of polishing, room temperature makes 1000 of soft capsule preparations.Oral, every day 2 times, each 3.
Embodiment 2: Fructus Ligustri Lucidi medical material 2500g, tea polyphenols 15g, olive oil 200g, perilla oil 200g, Cera Flava 2g
Get to pulverize and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 8 times of amount ethanol extractions 1.5 hours at every turn, merge extractive liquid,, filter, filtrate decompression is concentrated into 8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 20%, reflux 4 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 80 ℃ of relative densities, adds 8 times of molten diffusing extractum of water gaging, add 3～7% clarifiers (W/V), fully stir, left standstill 24 hours, filter, drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.Add Fructus Ligustri Lucidi extract, tea polyphenols, olive oil, perilla oil and Cera Flava in colloid mill, fully mix homogeneously is made 1000 of soft capsules according to conventional formulation technology, and every 0.5g is oral, every day 2 times, each 3.
Clarifier is " " powder clarifier ", Shanghai Jia Chuan chemical industry company limited is produced.
Embodiment 3: Fructus Ligustri Lucidi medical material 3000g, tea polyphenols 10g, olive oil 230g, perilla oil 230g
Get to pulverize and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 6 times of amount ethanol extractions 1.5 hours, merge extractive liquid, at every turn, filter, filtrate decompression is concentrated into 4 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 10%, reflux 6 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60 ℃ of relative densities, adds 6 times of molten diffusing extractum of water gaging, stirs evenly, regulate pH 2.0 with 20% hydrochloric acid solution, fully stir, add 3%NaCl (W/V) stirring and dissolving, left standstill 24 hours, filter, precipitation washes with water to pH 7.0, and drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.After getting gelatin 5g usefulness 60mL distilled water immersion 30min, in 60 ℃ of water-baths, dissolve to such an extent that gelatin solution is standby, light brown Fructus Ligustri Lucidi extract, tea polyphenols, olive oil and perilla oil are added in the gelatin solution, add 50 ℃ of distilled water after stirring to 100mL, stir, add the 60%Na of 50 ℃ of 200mL then
2SO
4Solution, mixing keeps mixed liquor at 50 ℃, stirs the 72%Na that adds 40 ℃ down
2SO
4Solution 500mL is chilled to 35 ℃ naturally, is placed in the ice-water bath below the rapid cooling to 10 ℃; constantly stir, add 37%HCHO solution 8mL, behind the stirring 20min; transfer to pH 9.0 with 20%NaOH, continue to stir 1h, centrifugal; divide and get microcapsule; it is formaldehydeless to be washed to neutrality, and lyophilization promptly gets exsiccant microcapsule; add adjuvant, make 1000 bags of powder 1000g or 1000 of capsules or 1000 in tablet or granules according to conventional formulation technology.
Embodiment 4: Fructus Ligustri Lucidi medical material 1500g, tea polyphenols 30g, olive oil 300g, perilla oil 300g
Get to pulverize and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 8 times of amount ethanol extractions 1.5 hours, merge extractive liquid, at every turn, filter, filtrate decompression is concentrated into 8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 20%, reflux 4 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 80 ℃ of relative densities, adds 4 times of molten diffusing extractum of water gaging, stirs evenly, regulate pH 1.0 with 25% hydrochloric acid solution, fully stir, add 4%NaCl (W/V) stirring and dissolving, left standstill 24 hours, filter, precipitation washes with water to pH 6.0, and drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.Get gelatin 10g, glycerol 30g and water 100ml mix homogeneously, in 80 ℃ of heating in water bath 1 hour, adding Fructus Ligustri Lucidi extract and tea polyphenols while hot stirs, be chilled to 65 ℃, get rubber cement, standby 65 ℃ of insulations, olive oil and perilla oil after the preheating, are slowly added 80ml water in 60 ℃ of water-baths, stir 30min and carry out emulsifying under constantly stirring, under constantly stirring, slowly add in the rubber cement emulsion, stir and carried out emulsifying in 4 hours, with dosing pump dropping-pill machine system, 13～15 ℃ of liquid Paraffin are made condensed fluid, constant pressure and dry makes 1000 of drop pills.Oral, every day 2 times, each 3.
Claims (10)
1. Chinese medicine preparation that is used for blood fat reducing and protects the liver is characterized in that: it is to add adjuvant by Fructus Ligustri Lucidi medical material 1000～3000g, tea polyphenols 10～30g, olive oil 100～400g and perilla oil 100～400g to be prepared from.
2. according to the described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 1, it is characterized in that: it is by Fructus Ligustri Lucidi medical material 2000g, tea polyphenols 20g, olive oil 250g and perilla oil 250g, adds adjuvant and is prepared from.
3. the preparation method of claim 1 or the 2 described Chinese medicine preparation that are used for blood fat reducing and protect the liver, it is characterized in that: get the Fructus Ligustri Lucidi medical material, through extract Fructus Ligustri Lucidi extract, add tea polyphenols, olive oil and perilla oil mix homogeneously then, add adjuvant routinely preparation process make various dosage forms.
4. according to the preparation method of the described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 3, it is characterized in that, described Fructus Ligustri Lucidi medical material is to extract like this: get the Fructus Ligustri Lucidi medical material, pulverize and be coarse powder, with alcohol reflux three times, add 6～8 times of amount ethanol extractions 2 hours, merge extractive liquid, at every turn, filter, filtrate decompression is concentrated into 4～8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 10～20%, reflux 4～6 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60～80 ℃ of relative densities, adds 6～8 times of molten diffusing extractum of water gaging, regulates pH to 1.0～2.0 with 20～25% hydrochloric acid solutions, fully stir, left standstill 24 hours, and filtered, precipitation washes with water to pH 7.0, drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.
5. according to the preparation method of the described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 3, it is characterized in that, described Fructus Ligustri Lucidi medical material is to extract like this: get pulverizing and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 6～8 times of amount ethanol extractions 2 hours, merge extractive liquid, at every turn, filter, filtrate decompression is concentrated into 4～8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 10～20%, reflux 4～6 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60～80 ℃ of relative densities, adds 4～8 times of molten diffusing extractum of water gaging, stirs evenly, regulate pH 1.0～2.0 with 20～25% hydrochloric acid solutions, fully stir, add 1～5%NaCl (W/V) stirring and dissolving, left standstill 24 hours, filter, precipitation washes with water to pH 6.0～7.0, and drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.
6. according to the preparation method of the described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 3, it is characterized in that, described Fructus Ligustri Lucidi medical material is to extract like this: get pulverizing and be the Fructus Ligustri Lucidi medical material of coarse powder, with alcohol reflux three times, add 6～8 times of amount ethanol extractions 2 hours at every turn, merge extractive liquid,, filter, filtrate decompression is concentrated into 4～8 times of Fructus Ligustri Lucidi medical material weight, adds the active carbon of Fructus Ligustri Lucidi medical material weight 10～20%, reflux 4～6 hours, filter, it is 1.10～1.20 extractum that filtrate decompression is concentrated into 60～80 ℃ of relative densities, adds 4～8 times of molten diffusing extractum of water gaging, stir evenly, add 3～7% clarifiers (W/V) and fully stir, left standstill 24 hours, filter, drying under reduced pressure gets the light brown Fructus Ligustri Lucidi extract.
7. according to the preparation method of the arbitrary described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 46, it is characterized in that: get Fructus Ligustri Lucidi extract, tea polyphenols, olive oil, perilla oil and Cera Flava 1～3g and place material-compound tank, rotating speed with 5000～7000r/min grinds, get oily mixture, cross 80～100 mesh sieves, get implant, make the softgel shell glue, adopt die pressing to make soft capsule with gelatin.
8. according to the preparation method of the described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 7, it is characterized in that, described die pressing is: the sprinkler body temperature is 50 ℃, typing is dry under 18～20 ℃, humidity＜30% condition, dynamically air-dry 6～12 hours, clean the capsule outside, polishing, dry in the air ball 12～16 hours of room temperature promptly gets soft capsule preparation.
9. according to the preparation method of the arbitrary described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 46, it is characterized in that: after getting gelatin 5g usefulness 60mL distilled water immersion 30min, in 60 ℃ of water-baths, dissolve to such an extent that gelatin solution is standby, with Fructus Ligustri Lucidi extract, tea polyphenols, olive oil and perilla oil add in the gelatin solution, add 50 ℃ of distilled water after stirring to 100mL, stir, add the 60%Na2SO4 solution of 50 ℃ of 200mL then, mixing, keep mixed liquor at 50 ℃, stir the 72%Na2SO4 solution 500mL that adds 35～45 ℃ down, be chilled to 32～35 ℃ naturally, be placed in the ice-water bath below the rapid cooling to 10 ℃, constantly stir, add 37%HCHO solution 8mL, behind the stirring 20min, transfer to pH 9.0 with 20%NaOH, continue to stir 1h, centrifugal, divide and get microcapsule, be washed to neutral formaldehydeless, lyophilization, promptly get exsiccant microcapsule, add adjuvant, make powder according to conventional formulation technology, capsule, tablet or granule.
10. according to the preparation method of the arbitrary described Chinese medicine preparation that is used for blood fat reducing and protects the liver of claim 46, it is characterized in that: get gelatin 5～20g, glycerol 15～40g and water 50～200ml mix homogeneously, in 60～100 ℃ of heating in water bath 1 hour, add Fructus Ligustri Lucidi extract while hot and tea polyphenols stirs, be chilled to 65 ℃, get rubber cement, standby 65 ℃ of insulations, with olive oil and perilla oil in 60 ℃ of water-baths after the preheating, under constantly stirring, add 20～100ml water, stir 30min and carry out emulsifying, emulsion is added in the rubber cement under constantly stirring, stir and carried out emulsifying in 4 hours, with dosing pump dropping-pill machine system, 13～15 ℃ of liquid Paraffin are made condensed fluid, and constant pressure and dry makes drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008103001439A CN101229233B (en) | 2008-01-18 | 2008-01-18 | Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008103001439A CN101229233B (en) | 2008-01-18 | 2008-01-18 | Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101229233A true CN101229233A (en) | 2008-07-30 |
| CN101229233B CN101229233B (en) | 2010-09-01 |
Family
ID=39896247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008103001439A Active CN101229233B (en) | 2008-01-18 | 2008-01-18 | Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101229233B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105054012A (en) * | 2015-07-28 | 2015-11-18 | 重庆市优胜科技发展有限公司 | Health-care product to scavenge active oxygen free radicals in body and regulate endogenous hormone levels |
| CN106214850A (en) * | 2016-08-03 | 2016-12-14 | 国药集团同济堂（贵州）制药有限公司 | A kind of blood fat reducing and the composition of natural products that protects the liver and preparation method thereof |
| JP2019099482A (en) * | 2017-11-30 | 2019-06-24 | 株式会社ファンケル | Polyphenols-containing soft capsule formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1167459C (en) * | 2002-12-13 | 2004-09-22 | 北京华源生命科贸发展有限公司 | Nutritive health food with functions of reducing blood fat and delaying senility and its prepn process |
| CN1792209A (en) * | 2006-01-13 | 2006-06-28 | 吕仕钧 | Fructus ligustri lucidi health-care tea, and its prepn. method |
| CN101053580A (en) * | 2006-11-10 | 2007-10-17 | 燕山大学 | New medical application of traditional Chinese medicine privet and preparation method of its extraction |
-
2008
- 2008-01-18 CN CN2008103001439A patent/CN101229233B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105054012A (en) * | 2015-07-28 | 2015-11-18 | 重庆市优胜科技发展有限公司 | Health-care product to scavenge active oxygen free radicals in body and regulate endogenous hormone levels |
| CN106214850A (en) * | 2016-08-03 | 2016-12-14 | 国药集团同济堂（贵州）制药有限公司 | A kind of blood fat reducing and the composition of natural products that protects the liver and preparation method thereof |
| JP2019099482A (en) * | 2017-11-30 | 2019-06-24 | 株式会社ファンケル | Polyphenols-containing soft capsule formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101229233B (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101234160B (en) | Fat-reducing and liver-protecting Chinese medicine preparation and preparation thereof | |
| CN105394749B (en) | A kind of Ricipe for health care food and preparation method and application containing astaxanthin | |
| CN106798762A (en) | One Plant Extracts and its preparation method and application | |
| CN101229233B (en) | Chinese traditional medicine preparation for antiatheroscloresis and liver-protection, and preparingng method thereof | |
| CN109662186A (en) | A kind of auxiliary reducing blood lipid pressed candy and preparation method thereof | |
| WO2015021631A1 (en) | Astragalus seed raw oil, refined oil, preparation method therefore and application thereof | |
| CN101999652A (en) | Blood fat-reducing health-care food and preparation method thereof | |
| CN103933411A (en) | Traditional Chinese medicinal composition for treating fatty liver, and preparation method and use thereof | |
| CN105616557A (en) | Self-emulsifying soft capsule with peony seed oil and application of self-emulsifying soft capsule to preparing blood fat reducing healthcare products or medicines | |
| CN105997925B (en) | Tanshinone IIA soft capsule and preparation method thereof | |
| CN106912952A (en) | A kind of preparation method of pharmaceutical composition and its capsule preparations with hypolipemic function | |
| CN105168520B (en) | A kind of preparation method of Caulis Kadsurae Coccineae extract and the application in treatment nonalcoholic fatty liver | |
| CN104873616B (en) | Application of the litchi rind polyphenol in the medicine or health products that reduce liver tg is prepared | |
| CN104940178A (en) | Medicine for hyperlipemia and atherosclerosis treating and preparation method and application | |
| CN103372175A (en) | Pharmaceutical composition as well as preparation method and application thereof | |
| CN105520847B (en) | A kind of heal-care essential oil and preparation method thereof containing JINHUAKUIZI oil | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN105412613B (en) | A kind of formula and its processing method for senile dementia | |
| CN105168434B (en) | A kind of health care product and preparation method thereof of complementary reducing blood lipid | |
| CN100409880C (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
| CN107213179A (en) | The concocting method and angelica sinensis powder of a kind of angelica sinensis | |
| CN108285827B (en) | Grape seed oil and preparation method thereof | |
| Xia et al. | Preparation of deer oil powder and its effect on acute gastric mucosal injury in rats | |
| CN101612296B (en) | Use of medicaments for treating cardiac-cerebral vascular diseases and post-stroke syndromes in preparation of medicaments for treating fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SINOPHARM GROUP TONGJITANG (GUIZHOU) PHARMACEUTICA Free format text: FORMER NAME: GUIZHOU TONGJITANG PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 550009 No. 296 Southwest Ring Road, Xiaohe District, Guizhou, Guiyang Patentee after: Sinopharm group (Guizhou) Pharmaceutical Co., Ltd. Address before: 550009 No. 296 Southwest Ring Road, Xiaohe District, Guizhou, Guiyang Patentee before: Guizhou Tongjitang Pharmaceutical Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |
Address after: 550009 Guiyang economic and Technological Development Zone, Guizhou Province, No. 99 Tongji Hall Patentee after: Sinopharm group (Guizhou) Pharmaceutical Co., Ltd. Address before: 550009 No. 296 Southwest Ring Road, Xiaohe District, Guizhou, Guiyang Patentee before: Sinopharm group (Guizhou) Pharmaceutical Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |